Bayer Cancer Drug Does Well in Trial - WSJ.com

Links shared publicly online about this topic.

237
total visits

Bayer Cancer Drug Does Well in Trial - WSJ.com

Bayer said positive results for its experimental prostate-cancer drug Alpharadin prompted an early halt to a clinical trial, possibly speeding the drug's path to approval in an increasingly crowded, multibillion-dollar market.

View full resource at online.wsj.com

Tags: Cancer, Cancer Medication, Prostate, Drug, Clinical Trial, Men's Health, Bayer

Most Recently Shared on June 7, 2011 at 1:56 pm By:

Susan S

Bayer Cancer Drug Does Well in Trial: Bayer said positive results for an experimental… http://goo.gl/fb/igZBn

12 months ago...

Retweet

Favorite

Also Shared By:

MedicalFeed

Regorafenib Does Well In Metastatic Colorectal Trial

medicalnewstoday.com — “The latest results on Bayer HealthCare's investigational compound regorafenib (BAY 73-4506) from the international, multicenter, randomized, double-blind, placebo-controlled Phase III CORRECT (Co” View full resource at medicalnewstoday.com

Most Recently Shared on January 21, 2012 at 2:05 am By:

MNT Cancer News Health News

Regorafenib Does Well In Metastatic Colorectal Trial http://t.co/uWUzZ9jF #cancer

4 months ago...

Retweet

Favorite

Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival - Drugs.com MedNews

drugs.com — “Positive Secondary Endpoint of Progression Free Survival Clinical Trial Program in Lung Cancer Ongoing Berlin, June 14, 2010 Bayer HealthCare and Onyx Pharmaceu” View full resource at drugs.com